Comparative Pharmacology
Head-to-head clinical analysis: HALAVEN versus NOVANTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALAVEN versus NOVANTRONE.
HALAVEN vs NOVANTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
None Documented
None Documented
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent